ArticleActa pharmaceutica Sinica. B2022
Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer
Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 192 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
192 citing papers in PubMed, 2 syntheses or guidelines pooled it, 296 citations in OpenAlex.
- Emerging Plant-Derived Exosome-Like Particles Reveal Key Therapeutic Benefits. A Comprehensive Review of Evidence.International journal of nanomedicine · 2025Pooled it
- Exosome-like nanoparticles derived from fruits, vegetables, and herbs: innovative strategies of therapeutic and drug delivery.Theranostics · 2024Pooled it
- Proteomic mapping of Rosa damascena nanovesicles reveals plastid mitochondrial metabolic convergence and antimicrobial peptides.Plant signaling & behavior · 2026Article
- Physicochemical Characterisation and In Vitro Bioactivity of Sumac (Rhus coriaria)-Derived Exosome-Like Nanoparticles.Chemistry & biodiversity · 2026Article
- Polyphenol‑based interventions in breast cancer: Signaling pathways, molecular mechanisms and translational therapeutic strategies (Review).Oncology reports · 2026Review
- Targeting the tumor microenvironment: a new strategy for natural products in breast cancer therapy.Natural products and bioprospecting · 2026Review
- Extracellular vesicles released by in vitro plant cell cultures: emerging systems for vesicle-mediated communication and biomedical translation.Plant cell reports · 2026Review
- Natural Product-Based Nanomedicine in the Treatment of Breast Cancer.Pharmaceutics · 2026Review
- Activation of cGAS-STING axis by CO@OMVs promote macrophage mitophagy for CIRI treatment.APL bioengineering · 2026Article
- Natural Product-Derived Vesicles in Nanotherapeutics.Journal of extracellular vesicles · 2026Review
- Extracellular Vesicles and Plant-Derived Vesicles in Cancer: From Mechanisms to Clinical Translation.Pharmaceutics · 2026Review
- Plant-Derived Exosome-like Nanovesicles for Metabolic Dysfunction-Associated Steatotic Liver Disease.Veterinary sciences · 2026Review
- Engineering Plant-Derived Exosome-like Nanoparticles as Bioinspired Nanocarriers: From Physicochemical Properties to Tumor Delivery Performance.Biomedicines · 2026Review
- Progress, Challenges, and Standardization Pathways in the Isolation and Purification Techniques of Plant-Derived Vesicles.Plants (Basel, Switzerland) · 2026Review
- Past, Present, and Future of Plant-Derived Extracellular Vesicles in Biomedical Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Extracellular Vesicles as a Potential Tool in Cancer Diagnosis and Therapy.Biomedicines · 2026Review
- Extracellular vesicles in solid tumors: from tumor ecology to engineered therapeutics.Molecular cancer · 2026Review
- Experimental Characterization Combined with Computational Network Analysis of Metabolites Associated with Chrysanthemum morifolium-derived exosome-like Nanoparticles in Predicting Potential AKI-relevant Targets.Cell biochemistry and biophysics · 2026Article
- Recent Progress in Exosome-Derived Nanocarriers for Breast Cancer Therapy: Advances, Translational Barriers, and Scale-Up Considerations.Pharmaceutical research · 2026Review
- Astragalus-derived nano-agonist potentiates chemotherapy by reducing tumor-suppressive macrophages.Acta pharmaceutica Sinica. B · 2026Article
132 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although several artificial nanotherapeutics have been approved for practical treatment of metastatic breast cancer, their inefficient therapeutic outcomes, serious adverse effects, and high cost of mass production remain crucial challenges. Herein, we developed an alternative strategy to specifically trigger apoptosis of breast tumors and inhibit their lung metastasis by using natural nanovehicles from tea flowers (TFENs). These nanovehicles had desirable particle sizes (131 nm), exosome-like morphology, and negative zeta potentials. Furthermore, TFENs were found to contain large amounts of polyphenols, flavonoids, functional proteins, and lipids. Cell experiments revealed that TFENs showed strong cytotoxicities against cancer cells due to the stimulation of reactive oxygen species (ROS) amplification. The increased intracellular ROS amounts could not only trigger mitochondrial damage, but also arrest cell cycle, resulting in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.